Nuvation Bio is trading 6.00% up now at $7.24 after the FDA granted Fast Track Designation on August 20, 2026, to investigational safusidenib for IDH1-mutant glioma.
- The designation supports expedited development and review for serious conditions with unmet medical needs.
- The company announced its SIGMA study has expanded into a pivotal Phase 3 trial.
- Broader U.S. equity futures are modestly higher, but the FDA milestone is the clearest catalyst.